Intuitive Surgical stock: Q3 growth meets legal charge

Intuitive Surgical reported strong operating growth for the quarter ended September 30, 2026, while a proposed antitrust settlement weighed on reported earnings. The company's October 20 earnings release said revenue increased 22 percent year over year.

Intuitive Surgical stock traded at 393.53 euros on Lang & Schwarz at 17:34:57 CET on Friday, October 30, 2026. That was 2.74 percent below the 404.63-euro quote in the latest report published at 11:24 CET the same day; this is a comparison since that report, not a Xetra day comparison.

Procedure growth supports revenue

Worldwide procedures using da Vinci and Ion systems rose approximately 15 percent. Da Vinci procedures increased about 14 percent and Ion procedures about 31 percent. Intuitive placed 546 da Vinci systems, including 315 da Vinci 5 systems, compared with 427 and 240, respectively, a year earlier.

The installed base reached 12,094 da Vinci systems at September 30, up 12 percent year over year, while the Ion installed base rose 21 percent to 1,152 systems. Instruments and accessories revenue increased 18 percent to 1.80 billion US dollars, and systems revenue reached 769 million US dollars.

Legal cost clouds reported profit

GAAP net income attributable to Intuitive Surgical fell to 522.8 million US dollars, or 1.49 US dollars per diluted share, from 704.4 million US dollars, or 1.95 US dollars, in the prior-year quarter. The result included a 450 million US dollar pretax charge linked to the proposed settlement of previously disclosed antitrust litigation.

Non-GAAP net income rose to 1.05 billion US dollars, or 3.00 US dollars per diluted share, from 867.2 million US dollars, or 2.40 US dollars. The company also recognized a 22 million US dollar after-tax benefit from refunds for earlier tariffs. The settlement remains subject to court approval and includes no admission of liability or wrongdoing.

Outlook keeps adoption central

Management expects worldwide da Vinci procedure growth of 14 percent to 15 percent in 2026, with results closer to the midpoint. It forecasts a non-GAAP gross margin of 68.7 percent to 69.3 percent and operating expense growth of 11 percent to 13 percent, assuming current tariffs remain in force through year-end.

Investors can follow the real-time quote of Intuitive Surgical stock as the market weighs procedure growth, system adoption, legal costs and tariff exposure.

The S&P 500 market coverage provides the relevant US market backdrop for Intuitive Surgical and other medical-technology shares.

More news and analyses are available on the Intuitive Surgical stock topic page.